Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00230334
Status:
TERMINATED
Last Update Posted:
2021-05-10
First Post:
2005-09-28
Brief Title:
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Sponsor:
Steven E Coutre
Organization:
Stanford University
Study Overview
Official Title:
Phase II Study of Gleevec Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome HES
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
terminated by PI due to insufficient accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the trial is to determine the safety and efficacy of Gleevec in idiopathic hypereosinophilic syndrome HES and to characterize the molecular basis for the therapeutic benefit of Gleevec in HES
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HEMMPD0001 | OTHER | OnCore | None |